Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies (Abstract #749)
Abstract details are now available.
https://meetings.asco.org/abstracts-presentations/229209
Background:
CF33-hNIS is a novel chimeric DNA vaccinia virus engineered with the human sodium-iodide symporter (hNIS) gene. CF33-hNIS selectively replicates in tumor cells leading to cell lysis and the release of tumor- and virus-associated antigens stimulating antitumor immunity. Here, we report results of patients with GI malignancies enrolled on a first-in-human phase 1 ascending, multiple dose, safety and tolerability study of CF33-hNIS, administered intratumorally (IT) or intravenously (IV) in adult patients with metastatic or advanced solid tumors (MAST).
Methods:
The MAST study is evaluating the safety of CF33-hNIS administered IT or IV, alone or in combination with pembrolizumab in patients with advanced or metastatic solid tumors with ≥ 2 prior lines of therapy (NCT05346484). CF33-hNIS is administered in 21-day cycles on C1D1 and C1D8, then D1 of each cycle thereafter. Pembrolizumab begins C2D1 for the combination groups and is administered Q3W. The co-primary endpoints are safety and to identify the recommended phase 2 dose. Secondary endpoints include objective response rate according to RECIST v1.1 and iRECIST, and to assess levels of viral replication via Single-Photon Emission Computerized Tomography (SPECT) with technetium-99.
Results:As of Aug 2023, we report early results from seven patients with GI malignancies who received CF33-hNIS alone, including: colorectal cancer (3), bile duct (2), pancreatic (1) and hepatocellular carcinoma (1). The disease control rate is 86%. Notably one patient with cholangiocarcinoma, treated IT with 3.0x107 PFU, presented with pseudoprogression with a 49% increase in tumor burden after two cycles of therapy. By the 4th cycle they achieved a complete response (CR) with no known recurrence. A second patient with bile duct cancer, who previously progressed on checkpoint blockade therapy, achieved stable disease for >5 months upon receiving IV-administered CF33-hNIS (3.0x107 PFU). Treatment-related adverse events for the CR patient included grade 1 fever and injection site reaction. All other patients experienced no treatment-related adverse events. SPECT analysis of the CR patient reveals intense levels of viral replication within the injected lesion and a concomitant increase in Th1 cytokines in cycle three that coordinated with tumor reduction. In-depth immunological changes in peripheral blood and on-treatment tumor biopsies will be presented.
Conclusions:
CF33-hNIS can replicate within cholangiocarcinoma lesions, as shown by SPECT imaging, and drive immunological changes known to promote antitumor immunity. CF33-hNIS monotherapy may be an effective and safe treatment option for GI malignancies, including cholangiocarcinoma, a rare disease with an unmet medical need. Treatment with CF33-hNIS monotherapy was well tolerated and the study has advanced to examine combination therapy with pembrolizumab. Clinical trial information: NCT05346484.
.
- Forums
- ASX - By Stock
- Why IMU is a multi multi bagger
Oncolytic virus CF33-hNIS monotherapy for the treatment of...
- There are more pages in this discussion • 2,856 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $505.0M |
Open | High | Low | Value | Volume |
7.0¢ | 7.1¢ | 6.8¢ | $1.427M | 20.55M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 57517 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 667419 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 24285 | 0.070 |
7 | 245456 | 0.069 |
29 | 1864632 | 0.068 |
21 | 2789852 | 0.067 |
15 | 2877680 | 0.066 |
Price($) | Vol. | No. |
---|---|---|
0.069 | 102230 | 6 |
0.070 | 467714 | 11 |
0.071 | 1621033 | 7 |
0.072 | 1875058 | 11 |
0.073 | 962338 | 7 |
Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
Last
6.9¢ |
  |
Change
0.000 ( 0.29 %) |
|||
Open | High | Low | Volume | ||
6.9¢ | 7.1¢ | 6.8¢ | 7149293 | ||
Last updated 15.59pm 21/05/2024 ? |
Featured News
IMU (ASX) Chart |
The Watchlist
ATC
ALTECH BATTERIES LTD
Martin Stein, CFO
Martin Stein
CFO
Previous Video
Next Video
SPONSORED BY The Market Online